Int Immunopharmacol. 2025 Aug 29;165:115449. doi: 10.1016/j.intimp.2025.115449. Online ahead of print.
ABSTRACT
Patient-derived tumor organoids, often referred to as tumor organoids, serve as in vitro tumor models for tumor-related research, such as living biobanks, identification of biomarkers, drug screening and personalized precision medicine. Despite great success of chimeric antigen receptor (CAR)-engineered T cell therapy of B cell malignancies, the efficacy of receptor-engineered immune cell therapy of solid tumors remains suboptimal due to the molecular heterogeneity and immunosuppressive tumor microenvironment. Moreover, direct and extensive clinical studies are limited because of the toxicity of drugs or adoptively transferred immune cells. Thus, more alternative studies using better in vitro models, such as organoids, are needed to identify the target molecules or biomarkers in tumor cells. Tumor organoids have emerged as a suitable in vitro model for evaluating therapeutic efficacy and toxicity of receptor-engineered immune cells (EICs), because 3D structure and genetic characteristics of tumor organoids mimic the solid tumor microenvironment. In this review, we have summarized the recent advances in the application of tumor organoids for innovating and analyzing immunotherapy of cancers using EICs. We have also highlighted their limitations and pinpointed the potential future research direction in order to better evaluate and improve EIC therapy of cancer.
PMID:40885089 | DOI:10.1016/j.intimp.2025.115449